The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 501–600 of 1,003
Harada, K., Baba, Y., Ishimoto, T., Kosumi, K., Tokunaga, R., Izumi, D., Ida, S., Imamura, Y., Iwagami, S., Miyamoto, Y., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4432-4 · Cited by 70
Jansen, M. P. H. M., Reijm, E. A., Sieuwerts, A. M., Ruigrok-Ritstier, K., Look, M. P., Rodríguez-González, F. G., Heine, A. A. J., Martens, J. W. M., Sleijfer, S., Foekens, J. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1877-4 · Cited by 70
Tretiakova, M., Wei, W., Boyer, H. D., Newcomb, L. F., Hawley, S., Auman, H. J., Vakar‐Lopez, F., McKenney, J. K., Fazli, L., Simko, J., et al. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.12 · Cited by 70
Britten, C. M., Janetzki, S., van der Burg, S. H., Huber, C. H., Kalos, M. D., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., O’Donnell-Tormey, J., Odunsi, K. O., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0940-z · Cited by 69
Parajuli, H., Teh, M., Abrahamsen, S., Christoffersen, I., Neppelberg, E., Lybak, S., Osman, T., Johannessen, A. C., Gullberg, D., Skarstein, K., et al. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12493 · Cited by 69
Ojerholm, E., Smith, A. M., Hwang, W., Baumann, B. C., Tucker, K. N., Lerner, S. P., Mamtani, R., Boursi, B., & Christodouleas, J. P. (2016) · Cancer · doi:10.1002/cncr.30422 · Cited by 69
FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
Richtmann, S., Wilkens, D., Warth, A., Lasitschka, F., Winter, H., Christopoulos, P., Herth, F. J. F., Muley, T., Meister, M. A., & Schneider, M. A. (2019) · Cancers · doi:10.3390/cancers11050652 · Cited by 64
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, J., Abeliovich, H., Acevedo‐Arozena, A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., et al. (2016) · Kölner Universitäts PublikationsServer (Universität zu Köln) · doi:10.5167/uzh-131237 · Cited by 69
Golouh, R., Čufer, T., Sadikov, A., Nussdorfer, P., Usher, P. A., Brünner, N., Schmitt, M., Lesche, R., Maier, S., Timmermans, M. A. M., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9724-3 · Cited by 69
Valladares‐Ayerbes, M., Blanco, M., Reboredo, M., Lorenzo-Patiño, M. J., Iglesias-Díaz, P., Haz‐Conde, M., Díaz‐Prado, S., Médina, V., Santamarina, I., Pértega-Díaz, S., et al. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13044367 · Cited by 69
White, N. M. A., Zhao, S. G., Zhang, J., Rozycki, E. B., Dang, H. X., McFadden, S. D., Eteleeb, A. M., Alshalalfa, M., Vergara, I. A., Erho, N., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.07.012 · Cited by 68
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis
Creemers, A., Krausz, S., Strijker, M., van der Wel, M. J., Soer, E. C., Reinten, R. J. A., Besselink, M. G., Wilmink, J. W., van de Vijver, M. J., van Noesel, C. J. M., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.08.002 · Cited by 69
Finkelmeier, F., Kronenberger, B., Zeuzem, S., Piiper, A., & Waidmann, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132119 · Cited by 69
Assessing p53 in clinical contexts: unlearned lessons and new perspectives
Hall, P. A., & McCluggage, W. G. (2005) · The Journal of Pathology · doi:10.1002/path.1913 · Cited by 69
Lee, C. K., Marschner, I. C., Simes, R. J., Voysey, M., Egleston, B. L., Hudes, G. R., & SOUZA, P. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3137 · Cited by 68
Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy
Forker, L. J., Choudhury, A., & Kiltie, A. E. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.06.002 · Cited by 70
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
Beelen, K. J., Zwart, W. T., & Linn, S. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.121 · Cited by 71
Sucheston, L. E., Zhao, H., Yao, S., Zirpoli, G., Liu, S., Barlow, W. E., Moore, H. C. F., Budd, G. T., Hershman, D. L., Davis, W., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1671-3 · Cited by 68
Walter, M. A., Meier, C., Radimerski, T., Iten, F., Kränzlin, M., Müller‐Brand, J., de Groot, J. W. B., Kema, I. P., Links, T. P., & Müller-Stich, B. P. (2009) · Cancer · doi:10.1002/cncr.24738 · Cited by 68
Vilmar, A. C., Santoni‐Rugiu, E., & Sørensen, J. B. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq053 · Cited by 68
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer
Boyle, D. P., McArt, D. G., Irwin, G. W., Wilhelm-Benartzi, C. S., Lioe, T. F., Sebastián, E., McQuaid, S., Hamilton, P. W., James, J. A., Mullan, P. B., et al. (2014) · Histopathology · doi:10.1111/his.12398 · Cited by 67
A Simplified Approach for the Molecular Classification of Glioblastomas
Mercier, M. L., Hastir, D., Lopez, X. M., Nève, N. D., Maris, C., Trépant, A., Rorive, S., Decaestecker, C., & Salmon, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045475 · Cited by 67
Tang, W., Liu, R., Yan, Y., Pan, X., Wang, M., Han, X., Ren, H. J., & Zhang, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.16582 · Cited by 67
Lorincz, A. T., Brentnall, A. R., Vasiljević, N., Scibior‐Bentkowska, D., Castañón, A., Fiander, A., Powell, N. G., Tristram, A. J., Cuzick, J. M., & Sasieni, P. D. (2013) · International Journal of Cancer · doi:10.1002/ijc.28050 · Cited by 65
Depicting the role of TP53 in hepatocellular carcinoma progression
Villanueva, A., & Hoshida, Y. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.018 · Cited by 67
Wartenberg, M., Zlobec, I., Perren, A. A., Koelzer, V. H., Gloor, B., Lugli, A., & Karamitopoulou, E. (2015) · Oncotarget · doi:10.18632/oncotarget.2775 · Cited by 64
MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma
Yang, H., Zheng, W., Shuai, X., Chang, R., Yu, L., Fang, F., & Yang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.4811 · Cited by 66
Koyanagi, K., O'Day, S. J., Boasberg, P. D., Atkins, M. B., Wang, H.-J., Gonzalez, R. C., Lewis, K. D., Thompson, J. A., Anderson, C. M., Lutzky, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0037 · Cited by 66
Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity
Munakata, K., Uemura, M., Tanaka, S., Kawai, K., Kitahara, T., Miyo, M., Kano, Y., Nishikawa, S., Fukusumi, T., Takahashi, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1945 · Cited by 66
Brunner, P., Jörg, A.-C., Glatz, K., Bubendorf, L., Radojewski, P., Umlauft, M., Marincek, N., Spanjol, P.-M., Krause, T., Dumont, R. A., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3486-2 · Cited by 66
Long Noncoding RNA HOTAIR as an Independent Prognostic Marker in Cancer: A Meta-Analysis
Zhang, S., Chen, S., Yang, G., Gu, F., Li, M., Zhong, B., Hu, J., Hoffman, A. R., & Chen, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105538 · Cited by 63
LINE-1 Methylation Level and Patient Prognosis in a Database of 208 Hepatocellular Carcinomas
Harada, K., Baba, Y., Ishimoto, T., Chikamoto, A., Kosumi, K., Hayashi, H., Nitta, H., Hashimoto, D., Beppu, T., & Baba, H. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4134-3 · Cited by 66
Linn, S. C., & Veer, L. V. ‘. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70012-7 · Cited by 64
Popat, S., Chen, Z., Zhao, D., Pan, H., Hearle, N., Chandler, I. R., Shao, Y., Aherne, W., & Houlston, R. S. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl301 · Cited by 65
Yang, S. X., Costantino, J. P., Kim, C., Mamounas, E. P., Nguyen, D., Jeong, J., Wolmark, N., Kidwell, K., Paik, S., & Swain, S. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1602 · Cited by 65
Beelen, K. J., Opdam, M., Severson, T., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J. F., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3606 · Cited by 66
Molecular Biomarkers in Advanced Renal Cell Carcinoma
Maroto, P., & Rini, B. I. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1351 · Cited by 64
What Information Should Be Required to Support Clinical “Omics” Publications?
Baggerly, K., & Coombes, K. R. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.158618 · Cited by 64
Paoletti, C., Schiavon, G., Dolce, E. M., Darga, E. P., Carr, T. H., Geradts, J., Hoch, M., Klinowska, T. C. M., Lindemann, J. P. O., Marshall, G. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1569 · Cited by 66
Simsek, S., Kursuncu, U., Kıbış, E. Y., AnisAbdellatif, M., & Dağ, A. (2019) · Expert Systems with Applications · doi:10.1016/j.eswa.2019.112863 · Cited by 67
EGFR as a stable marker of prostate cancer dissemination to bones
Nastały, P., Stoupiec, S., Popęda, M., Smentoch, J., Schlomm, T., Morrissey, C. M., Zaczek, A. J., Beyer, B., Tennstedt, P., Graefen, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01052-8 · Cited by 67
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer
Abdel-Fatah, T. M. A., Sultana, R., Abbotts, R., Hawkes, C., Seedhouse, C., Chan, S. Y. T., & Madhusudan, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.27980 · Cited by 64
Custodio, A., González-Larriba, J. L., Bobokova, J., Calles, A., Álvarez-Gallego, R., Cuadrado, E., Manzano, A., & Díaz‐Rubio, E. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a4b8fb · Cited by 65
Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also
Bartlett, J. M. S., McConkey, C. C., Munro, A. F., Desmedt, C., Dunn, J., Larsimont, D., O’Malley, F. P., Cameron, D., Earl, H. M., Poole, C. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.7869 · Cited by 64
Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
Kok, M., Holm, C., Hauptmann, M., Michalides, R. J. A. M., Stål, O., Linn, S. C., & Landberg, G. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp412 · Cited by 64
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers
Okadome, K., Baba, Y., Nomoto, D., Yagi, T., Kalikawe, R., Harada, K., Hiyoshi, Y., Nagai, Y., Ishimoto, T., Iwatsuki, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0811-0 · Cited by 65
Tubbs, R., Barlow, W. E., Budd, G. T., Swain, E., Porter, P. L., Gown, A. M., Yeh, I.-T., Sledge, G. W., Shapiro, C. L., Ingle, J. N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1566 · Cited by 64
Zhang, L. Q., Wang, J., Jiang, F., Xu, L., Liu, F. Y., & Yin, R. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034100 · Cited by 63
Paxton, D., & Pauling, J. D. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.02.005 · Cited by 63
Nieto, Y. L., Woods, J., Nawaz, F., Baron, A. D., Jones, R. B., Shpall, E. J., & Nawaz, S. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603875 · Cited by 63
Chen, M.-L., Cai, E.-H., Huang, J., Yu, P., & Li, K. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0020 · Cited by 65
Muftah, A. A., Aleskandarany, M. A., Al-kaabi, M. M., Sonbul, S. N., Diez, M., Nolan, C. C., Caldas, C., Ellis, I. O., Rakha, E. A., & Green, A. R. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4270-0 · Cited by 63
Sand, F. L., Nielsen, D. M. B., Frederiksen, M. H., Rasmussen, C. L., & Kjær, S. K. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.10.015 · Cited by 63
Wang, Y.-Q., Zhang, Y. X., Jiang, W., Chen, Y., Xu, S., Liu, N., Zhao, Y., Li, L., Lei, Y., Hong, X.-H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0752-4 · Cited by 63
Xing, X., Shi, J., Jia, Y., Dou, Y., Li, Z., Dong, B., Guo, T., Cheng, X., Li, X., Du, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003984 · Cited by 63
van Kruchten, M., Glaudemans, A. W. J. M., de Vries, E. F. J., Schröder, C. P., de Vries, E. G. E., & Hospers, G. A. P. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3107-5 · Cited by 62
Thoms, J., Pra, A. D., Anborgh, P. H., Christensen, E. N., Fleshner, N. E., Ménard, C. M., Chadwick, K., Milosevic, M., Catton, C., Pintilie, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.345 · Cited by 62
Circulating Serum Trefoil Factor 3 (TFF3) Is Dramatically Increased in Chronic Kidney Disease
Du, T.-Y., Luo, H.-M., Qin, H.-C., Wang, F., Wang, Q., Xiang, Y., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080271 · Cited by 62
Lee, T. K., Murthy, S. R. K., Cawley, N. X., Dhanvantari, S., Hewitt, S. M., Lou, H., Lau, T. C. M., Ma, S., Huynh, T., WESLEY, R. A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci40433 · Cited by 62
RetractedJonsson, L., Bergman, J., Nodin, B., Manjer, J., Pontén, F., Uhlén, M., & Jirström, K. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-114 · Cited by 62
Urquidi, V., Steve Goodison, B., Kim, J.-S., Chang, M. N., Dai, Y. E., & Rosser, C. J. (2012) · Urology · doi:10.1016/j.urology.2012.01.016 · Cited by 62
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
Casadevall, D., Gimeno, J., Clavé, S., Taus, Á., Pijuán, L., Arumí, M., Lorenzo, M., Menéndez, S., Cañadas, I., Albanell, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3976 · Cited by 64
Bottai, G., Raschioni, C., Székely, B., Tommaso, L. D., Szász, A. M., Losurdo, A., Győrffy, B., Ács, B., Torrisi, R., Karachaliou, N., et al. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2016.33 · Cited by 61
Radiogenomics and radiotherapy response modeling
Naqa, I. E., Kerns, S. L., Coates, J. T. T., Luo, Y., Speers, C. W., West, C., Rosenstein, B. S., & Haken, R. K. T. (2017) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aa7c55 · Cited by 61
Vangangelt, K. M. H., van Pelt, G. W., Engels, C. C., Putter, H., Liefers, G., Smit, V. T. H. B. M., Tollenaar, R. A. �. �., Kuppen, P. J. K., & Mesker, W. E. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4617-6 · Cited by 62
Yamagishi, T., Fujimoto, N., Nishi, H., Miyamoto, Y., Hara, N., Asano, M., Fuchimoto, Y., Wada, S., Kitamura, K., Ozaki, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.014 · Cited by 61
Rossi, E. M. C., Fassan, M., Aieta, M., Zilio, F., Celadin, R., Borin, M., Grassi, A., Troiani, L., Basso, U., Barile, C., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.388 · Cited by 61
Serrero, G., Hawkins, D. M., Yue, B., Ioffe, O. B., Bejarano, P. A., Phillips, J. T., Head, J. F., Elliott, R. L., Tkaczuk, K., Godwin, A. K., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3111 · Cited by 61
Lyng, M., Lænkholm, A., Søkilde, R., Thomsen, K. G., Litman, T., & Ditzel, H. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036170 · Cited by 61
Liu, N. Q., Marchi, T. D., Timmermans, A. M., Beekhof, R., Trapman-Jansen, A., Foekens, R., Look, M. P., van Deurzen, C. H. M., Span, P. N., Sweep, F. C. G. J., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.037176 · Cited by 61
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
Liikanen, I., Koski, A., Merisalo-Soikkeli, M., Hemminki, O., Oksanen, M., Kairemo, K., Joensuu, T. K., Kanerva, A., & Hemminki, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.989771 · Cited by 62
New paradigms in translational science research in cancer biomarkers
Wagner, P. D., & Srivastava, S. (2012) · Translational research · doi:10.1016/j.trsl.2012.01.015 · Cited by 61
Pastushenko, I., Vermeulen, P., Carapeto, F. J., den Eynden, G. V., Rutten, A., Ara, M., Dirix, L. Y., & Laere, S. V. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12688 · Cited by 61
Bertucci, F., Finetti, P., Viens, P., & Birnbaum, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.014 · Cited by 61
Neuron-Specific Enolase as an Immunohistochemical Marker Is Better Than Its Reputation
Mjønes, P., Sagatun, L., Nordrum, I. S., & Waldum, H. L. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417733676 · Cited by 61
Pozner-Moulis, S., Cregger, M. A., Camp, R. L., & Rimm, D. L. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700515 · Cited by 61
Collins, P. G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12376 · Cited by 62
Self-citationSpatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression
Fassler, D., Torre-Healy, L. A., Gupta, R., Hamilton, A. M., Kobayashi, S., Alsten, S. C. V., Zhang, Y., Kurç, T., Moffitt, R. A., Troester, M. A., et al. (2022) · Cancers · doi:10.3390/cancers14092148 · Cited by 62
Zhao, Z., Ge, J., Sun, Y., Tian, L., Lu, J., Liu, M., & Zhao, Y. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.02.024 · Cited by 60
Nielsen, K. V., Ejlertsen, B., Müller, S., Möller, S., Rasmussen, B., Balslev, E., Lænkholm, A., Christiansen, P., & Mouridsen, H. T. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0984-y · Cited by 60
Abdel-Fatah, T. M. A., Arora, A., Moseley, P. M., Coveney, C., Perry, C., Johnson, K., Kent, C. D., Ball, G., Chan, S. Y. T., & Madhusudan, S. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.08.001 · Cited by 60
Paulsen, E., Kilvaer, T. K., Rakaee, M., Maurseth, R. J., Al‐Saad, S., Hald, S. M., Al-Shibli, K. I., Andersen, S., Richardsen, E. H., Busund, L., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.11.004 · Cited by 60
The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors
López‐Knowles, E., Hernandez, S. F., Kogevinas, M., Lloreta, J., Amorós, À., Tardón, A., Carrato, A., Kishore, S. A., Serra, C., Malats, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0206 · Cited by 60
Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers
Bjartell, A. S., Montironi, R., Berney, D. M., & Egevad, L. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.531284 · Cited by 59
Loibl, S., Treue, D., Budczies, J., Weber, K. E., Stenzinger, A., Schmitt, W., Weichert, W., Jank, P., Furlanetto, J., Klauschen, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3258 · Cited by 59
Bidard, F., Belin, L., Delaloge, S., Lerebours, F., Ngô, C., Reyal, F., Alran, S., Giacchetti, S., Marty, M. E., Lebofsky, R., et al. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/130470 · Cited by 59
Schlichting, J. A., Soliman, A. S., Schairer, C., Schottenfeld, D., & Merajver, S. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2133-2 · Cited by 59
DNA methylation: potential biomarker in Hepatocellular Carcinoma
Mah, W.-C., & Lee, C. G. L. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-5 · Cited by 59
Beije, N., Onstenk, W., Kraan, J., Sieuwerts, A. M., Hamberg, P., Dirix, L. Y., Brouwer, A., de Jongh, F. E., Jager, A., Seynaeve, C., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.007 · Cited by 59
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
Altan, M., Kidwell, K., Pelekanou, V., Carvajal‐Hausdorf, D., Schalper, K. A., Toki, M. I., Thomas, D. G., Sabel, M. S., Hayes, D. F., & Rimm, D. L. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0095-1 · Cited by 59
Zhang, Y., Storr, S. J., Johnson, K., Green, A. R., Rakha, E. A., Ellis, I. O., Morgan, D. A. L., & Martin, S. G. (2014) · Oncotarget · doi:10.18632/oncotarget.2683 · Cited by 59
Lee, J. S., Park, S., Park, J. M., Cho, J. H., Kim, S. I., & Park, B. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2695-7 · Cited by 58
Mesothelin expression is associated with poor outcomes in breast cancer
Li, Y. R., Xian, R. R., Ziober, A. F., Conejo-Garcia, J. R., Perales‐Puchalt, A., June, C. H., Zhang, P. J., & Tchou, J. C. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3077-5 · Cited by 58
Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials
Varu, V. N., Tsihlis, N. D., & Kibbe, M. R. (2008) · Vascular and Endovascular Surgery · doi:10.1177/1538574408322752 · Cited by 59
Stromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer
MacKenzie, T. A., Schwartz, G. N., Calderone, H. M., Graveel, C. R., Winn, M. E., Hostetter, G. H., Wells, W. A., & Sempere, L. F. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.08.020 · Cited by 60
Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis
Bradbury, P. A., Zhai, R., Ma, C., Xu, W., Hopkins, J., Kulke, M. H., Asomaning, K., Wang, Z., Su, L., Heist, R. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0192 · Cited by 58
Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers
Green, A. R., Aleskandarany, M. A., Ali, R., Hodgson, E. G., Atabani, S., DeSouza, K., Rakha, E. A., Ellis, I. O., & Madhusudan, S. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0195 · Cited by 58
Bruun, J., Sveen, A., Barros, R., Eide, P. W., Eilertsen, I. A., Kolberg, M., Pellinen, T. S., David, L., Svindland, A., Kallioniemi, O., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12347 · Cited by 58
Lundberg, A., Lindström, L. S., Li, J., Harrell, J. C., Darai‐Ramqvist, E., Sifakis, E. G., Foukakis, T., Perou, C. M., Czene, K., Bergh, J. C. S., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1121-4 · Cited by 59
Aleskandarany, M. A., Rakha, E. A., Ahmed, M. A. H., Powe, D. G., Ellis, I. O., & Green, A. R. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1012-y · Cited by 57
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
